Figure 4
Figure 4. Local application of CP 55940 reduces CFA-induced pain in BERK and hBERK1 mice. PWF was assessed by the application of 1.0 g of von Frey filament in 10-month-old BERK (A) and 8-month-old male hBERK1 (B) mice and age- and sex-matched HbA-BERK mice. PWFs were recorded before and for 24 hours after injecting 10 μg (in 10 μL) of CFA. Then, 10 μg (in 10 μL) of CP 55940 or vehicle was injected in the same hind paw, and PWF recorded over another 6 hours. Data are shown as mean ± SEM from 4 mice with 3 observations per mouse. Significance of differences: In panel A: *P < .05, after CFA versus baseline (before CFA); †P < .01, immediately before versus after administration of CP 55940; ‡P < .01, CP 55940 versus vehicle at the same time point. In panel B: *P < .01, after CFA versus baseline (before CFA); †P < .01, CP 55940 versus vehicle at the same time point; ‡P < .01, immediately before versus after administration of CP 55940.

Local application of CP 55940 reduces CFA-induced pain in BERK and hBERK1 mice. PWF was assessed by the application of 1.0 g of von Frey filament in 10-month-old BERK (A) and 8-month-old male hBERK1 (B) mice and age- and sex-matched HbA-BERK mice. PWFs were recorded before and for 24 hours after injecting 10 μg (in 10 μL) of CFA. Then, 10 μg (in 10 μL) of CP 55940 or vehicle was injected in the same hind paw, and PWF recorded over another 6 hours. Data are shown as mean ± SEM from 4 mice with 3 observations per mouse. Significance of differences: In panel A: *P < .05, after CFA versus baseline (before CFA); †P < .01, immediately before versus after administration of CP 55940; ‡P < .01, CP 55940 versus vehicle at the same time point. In panel B: *P < .01, after CFA versus baseline (before CFA); †P < .01, CP 55940 versus vehicle at the same time point; ‡P < .01, immediately before versus after administration of CP 55940.

Close Modal

or Create an Account

Close Modal
Close Modal